Cargando…

sHIV-1 drug resistance in people on dolutegravir-based ART: Collaborative analysis of cohort studies

BACKGROUND: The widespread use of the integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) in first- and second-line antiretroviral therapy (ART) may facilitate emerging resistance. We combined data from HIV cohorts to examine patterns of drug resistance mutations (DRMs) and identify risk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Loosli, Tom, Hossmann, Stefanie, Ingle, Suzanne M., Okhai, Hajra, Kusejko, Katharina, Mouton, Johannes, Bellecave, Pantxika, van Sighem, Ard, Stecher, Melanie, d’Arminio Monforte, Antonella, Gill, M. John, Sabin, Caroline A., Maartens, Gary, Günthard, Huldrych F., Sterne, Jonathan A. C., Lessells, Richard, Egger, Matthias, Kouyos, Roger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10104228/ https://www.ncbi.nlm.nih.gov/pubmed/37066200 http://dx.doi.org/10.1101/2023.04.05.23288183

Ejemplares similares

Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients
por: Olearo, Flaminia, et al.
Publicado: (2019)

Corrigendum to: Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients
por: Olearo, Flaminia, et al.
Publicado: (2019)

Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study
por: Hauser, Anthony, et al.
Publicado: (2020)

Adverse events of raltegravir and dolutegravir
por: Elzi, Luigia, et al.
Publicado: (2017)

Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies
por: Kaulich-Bartz, Josee, et al.
Publicado: (2013)

Editorial Commentary: The Irreversibility of HIV Drug Resistance
por: Kouyos, Roger D., et al.
Publicado: (2015)

How effectively can HIV phylogenies be used to measure heritability?
por: Shirreff, George, et al.
Publicado: (2013)

Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort
por: Mondi, Annalisa, et al.
Publicado: (2019)

Dolutegravir Monotherapy as Maintenance Strategy: A Meta-Analysis of Individual Participant Data From Randomized Controlled Trials
por: Fournier, Anna L, et al.
Publicado: (2022)

Parameter estimates for trends and patterns of excess mortality among persons on antiretroviral therapy in high-income European settings
por: Trickey, Adam, et al.
Publicado: (2019)

Migrating a Well-Established Longitudinal Cohort Database From Oracle SQL to Research Electronic Data Entry (REDCap): Data Management Research and Design Study
por: Kusejko, Katharina, et al.
Publicado: (2023)

Phylodynamics on local sexual contact networks
por: Rasmussen, David A., et al.
Publicado: (2017)

Weight gain on dolutegravir: Association is not the same as causation
por: Maartens, Gary, et al.
Publicado: (2023)

HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review
por: Patel, Rickesh, et al.
Publicado: (2021)

Dolutegravir for second-line treatment: Programmatic implications of new evidence
por: Zhao, Ying, et al.
Publicado: (2022)

Absence of Proviral Human Immunodeficiency Virus (HIV) Type 1 Evolution in Early-Treated Individuals With HIV Switching to Dolutegravir Monotherapy During 48 Weeks
por: Jörimann, Lisa, et al.
Publicado: (2023)

Sustained Viral Suppression With Dolutegravir Monotherapy Over 192 Weeks in Patients Starting Combination Antiretroviral Therapy During Primary Human Immunodeficiency Virus Infection (EARLY-SIMPLIFIED): A Randomized, Controlled, Multi-site, Noninferiority Trial
por: West, Emily, et al.
Publicado: (2023)

Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV
por: Kusejko, Katharina, et al.
Publicado: (2020)

Is weak CD4+ gain in the course of suppressive combination antiretroviral therapy for HIV infection a current clinical challenge? A case report and brief review of the literature
por: Tincati, Camilla, et al.
Publicado: (2018)

Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation
por: Braun, Dominique L., et al.
Publicado: (2020)

Reply to Manfredi
por: Lichtner, Miriam, et al.
Publicado: (2015)

Assessment of Overlap of Phylogenetic Transmission Clusters and Communities in Simple Sexual Contact Networks: Applications to HIV-1
por: Villandre, Luc, et al.
Publicado: (2016)

Do Combination Antiretroviral Therapy Regimens for HIV Infection Feature Diverse T-Cell Phenotypes and Inflammatory Profiles?
por: Tincati, Camilla, et al.
Publicado: (2020)

Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study
por: Kusejko, Katharina, et al.
Publicado: (2018)

An Approach to Quantifying the Interaction between Behavioral and Transmission Clusters
por: Salazar-Vizcaya, Luisa, et al.
Publicado: (2022)

HIV-1 integration sites in CD4(+) T cells during primary, chronic, and late presentation of HIV-1 infection
por: Kok, Yik Lim, et al.
Publicado: (2021)

Efficient immune reconstitution in HIV+ naïve patients (pts) starting a first lopinavir/ritonavir-containing regimen with low CD4 counts
por: Merlini, E, et al.
Publicado: (2010)

Effectiveness of hydroxychloroquine in COVID-19 disease: A done and dusted deal?
por: d’Arminio Monforte, Antonella, et al.
Publicado: (2020)

Six-month immune responses to mRNA-1273 vaccine in combination antiretroviral therapy treated late presenter people with HIV according to previous SARS-CoV-2 infection
por: Augello, Matteo, et al.
Publicado: (2023)

Immunologic characterization of a patient with clinical and virologic rebound upon Nirmatrelvir/Ritonavir treatment: the unfortunate epilogue of COVID-19
por: Marchetti, Giulia, et al.
Publicado: (2023)

The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis
por: Marzel, Alex, et al.
Publicado: (2018)

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
por: Mahomed, Kairoonisha, et al.
Publicado: (2020)

Assessing the drivers of syphilis among men who have sex with men in Switzerland reveals a key impact of screening frequency: A modelling study
por: Balakrishna, Suraj, et al.
Publicado: (2021)

Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link
por: Nguyen, Huyen, et al.
Publicado: (2021)

Role of In Vitro Stimulation with Lipopolysaccharide on T-Cell Activation in HIV-Infected Antiretroviral-Treated Patients
por: Tincati, Camilla, et al.
Publicado: (2012)

Evidence for Polymicrobic Flora Translocating in Peripheral Blood of HIV-Infected Patients with Poor Immune Response to Antiretroviral Therapy
por: Merlini, Esther, et al.
Publicado: (2011)

Heightened Circulating Interferon-Inducible Chemokines, and Activated Pro-Cytolytic Th1-Cell Phenotype Features Covid-19 Aggravation in the Second Week of Illness
por: Tincati, Camilla, et al.
Publicado: (2020)

Impact of daily versus weekly service of infectious diseases consultation on hospital antimicrobial consumption: a retrospective study
por: Cona, Andrea, et al.
Publicado: (2020)

Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors
por: Rovito, Roberta, et al.
Publicado: (2022)

Monkeypox epidemic in prisons: How to prevent it?
por: Cocco, N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lmt3eiouh3bmgi8j98l8elg443